These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 1452928)
61. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure. Quyyumi AA; Wagstaff D; Evans TR Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162 [TBL] [Abstract][Full Text] [Related]
62. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. Halperin JL; Faxon DP; Creager MA; Bass TA; Melidossian CD; Gavras H; Ryan TJ Am J Cardiol; 1982 Nov; 50(5):967-72. PubMed ID: 6182786 [TBL] [Abstract][Full Text] [Related]
63. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750 [TBL] [Abstract][Full Text] [Related]
64. [Evaluation of the hemodynamic effects of the long-acting peripheral vasodilator flosequinan in patients with chronic heart failure]. Abdurakhmanov US; Naumov VG; Shevliagin SA; Novikov SV; Mareev VIu; Belenkov IuN Kardiologiia; 1991 Nov; 31(11):49-51. PubMed ID: 1805065 [TBL] [Abstract][Full Text] [Related]
65. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411 [TBL] [Abstract][Full Text] [Related]
66. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure. Riegger GA; Kahles H; Wagner A; Kromer EP; Elsner D; Kochsiek K Cardiovasc Drugs Ther; 1990 Oct; 4(5):1395-402. PubMed ID: 1980598 [TBL] [Abstract][Full Text] [Related]
67. Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. Baumann G; Ningel K; Permanetter B J Cardiovasc Pharmacol; 1989 May; 13(5):730-8. PubMed ID: 2472521 [TBL] [Abstract][Full Text] [Related]
68. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Lepore JJ; Maroo A; Bigatello LM; Dec GW; Zapol WM; Bloch KD; Semigran MJ Chest; 2005 May; 127(5):1647-53. PubMed ID: 15888841 [TBL] [Abstract][Full Text] [Related]
69. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function. Capomolla S; Pozzoli M; Opasich C; Febo O; Riccardi G; Salvucci F; Maestri R; Sisti M; Cobelli F; Tavazzi L Am Heart J; 1997 Dec; 134(6):1089-98. PubMed ID: 9424070 [TBL] [Abstract][Full Text] [Related]
70. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. Binkley PF; Nunziata E; Cody RJ Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595 [TBL] [Abstract][Full Text] [Related]
71. Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. Galie N; Branzi A; Magnani G; Melandri G; Caldarera I; Rapezzi C; Grattoni C; Magnani B Cardiovasc Drugs Ther; 1993 Jun; 7(3):337-47. PubMed ID: 8364004 [TBL] [Abstract][Full Text] [Related]
72. Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside. Fifer MA; Colucci WS; Lorell BH; Jaski BE; Barry WH J Am Coll Cardiol; 1985 Mar; 5(3):731-7. PubMed ID: 3973272 [TBL] [Abstract][Full Text] [Related]
73. Trimazosin in chronic congestive heart failure: improved left ventricular function at rest and during exercise. Ports TA; Chatterjee K; Wilkinson P; Avakian D; Parmley WW Am Heart J; 1983 Nov; 106(5 Pt 1):1036-42. PubMed ID: 6139004 [TBL] [Abstract][Full Text] [Related]
74. Importance of venodilation during long-term vasodilator therapy of chronic left ventricular failure. Franciosa JA; Leddy CL; Schwartz DE Z Kardiol; 1983; 72 Suppl 3():168-72. PubMed ID: 6666217 [TBL] [Abstract][Full Text] [Related]
75. Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure. Bellissant E; Annane D; Pussard E; Thuillez C; Giudicelli JF Fundam Clin Pharmacol; 1996; 10(2):127-35. PubMed ID: 8737955 [TBL] [Abstract][Full Text] [Related]